Reversal Agents in Development for the New Oral Anticoagulants

References

• . Wysowki DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167(13): 1414–1419
   PubMedGoogle Scholar
• . Budnitz DS, Lovegrove MC, Shebab N, Richards CL. Emergency hospitalization for adverse drug events in older Americans. N Eng J Med. 2011;365(21):2002–2012
   PubMed Web of Science ®Google Scholar
• . Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160(1):41–46
   PubMedGoogle Scholar
• . Choudhry NK, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GH. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med. 2006;119(7):607–615
   PubMed Web of Science ®Google Scholar
• . Nieuwlaat R, Capucci A, Camm AJ,; European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22):2422–2434
   PubMed Web of Science ®Google Scholar
• . Casciano JP, Singer DE, Kwong WJ, Fox ES, Martin BC. Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use. Am J Cardiovasc Drugs. 2012;12(5):313–323
   PubMed Web of Science ®Google Scholar
• . McConeghy K, Bress A, Wing C. Reports of bleeding-related fatalities with dabigatran and warfarin: an analysis using the Food and Drug Administration Adverse Events Reporting System [abstract]. J Am Coll Cardiol. 2013;61(10–S):Abstract E319
   Web of Science ®Google Scholar
• . Radecki RP. Dabigatran: uncharted waters and potential harms [published correction appears in Ann Intern Med. 2012;157(5):388]. Ann Intern Med. 2012;157(1):66–68
   PubMed Web of Science ®Google Scholar
• . Beyer-Westendorf J, Förster K, Pannach S,. Rates, management and outcome of bleeding complications during rivaroxaban therapy in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955–962
   PubMed Web of Science ®Google Scholar
• . PRADAXA (dabigatran etexilate mesylate) capsules for oral use. Prescribing Information. Boehringer Ingelheim Pharmaceuticals, Inc. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Revised September 2014. Accessed August 26, 2014
   Google Scholar
• . Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm. 2012;69(17):1473–1484
   PubMed Web of Science ®Google Scholar
• . Kaatz S, Kouides PA, Garcia DA,. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87( Suppl 1):S141–S145
   PubMed Web of Science ®Google Scholar
• . Beriplex® P/N 100 Prescribing Information. http://labeling.cslbehring.com/PI/CORE/Beriplex/EN/Beriplex-Prescribing-Information.pdf. Accessed October 14, 2014
   Google Scholar
• . Bauer KA. Reversal of antithrombotic agents. Am J Hematol. 2012;87( Suppl 1):S119–S126
   Web of Science ®Google Scholar
• . Schiele F, van Ryn J, Canada K,. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121(18):3554–3562
   PubMed Web of Science ®Google Scholar
• . Glund S, Stangier J, Schmohl M,. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers [abstract]. Circulation. 2013;128(22):A17765
   Web of Science ®Google Scholar
• . National Institutes of Health. Reversal of dabigatran anticoagulant effect with idarucizumab. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02104947. Updated October 7, 2014. Accessed October 10, 2014
   Google Scholar
• . International Nonproprietary Names for Pharmaceutical Substances (INN): Andexanet alfa. WHO Drug Information, Vol 27(4):402–403. http://apps.who.int/medicinedocs/documents/s21316en/s21316en.pdf. Accessed October 12, 2014
   Google Scholar
• . Crowther M, Kitt M, Lorenz T,. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors [abstract]. J Thromb Haemost. 2013;11( Suppl 2):30. Abstract AS20.1. http://onlinelibrary.wiley.com/doi/10.1111/jth.12284/pdf
   Web of Science ®Google Scholar
• . Lu G, DeGuzman FR, Hollenbach SJ,. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–451
   PubMed Web of Science ®Google Scholar
• . Crowther M, Vandana M, Michael K,. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors [abstract]. Blood. 2013;122(21):Abstract 3636. http://www.bloodjournal.org/content/122/21/3636
   Web of Science ®Google Scholar
• . National Institutes of Health. A study in older subject to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation effect of rivaroxaban. Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT02220725. Updated October 7, 2014. Accessed October 10, 2014
   Google Scholar
• . National Institutes of Health. A study in older subjects to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation of apixaban. Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT02207725. Updated July 31, 2014. Accessed September 29, 2014
   Google Scholar
• . Laulicht B, Bakhru S, Jiang X,. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977 [abstract]. J Thromb Haemost. 2013;11( Suppl 2):76. Abstract AS47.1. http://onlinelibrary.wiley.com/doi/10.1111/jth.12284/pdf
   Web of Science ®Google Scholar
• . Bakhru S, Laulicht B, Jiang X,. PER977 (PER977) preliminary first in human results. Circulation. 2013;128( Suppl 22):Abstract 18809
   Google Scholar
• . National Institutes of Health. Effects of a double-blind, single dose of PER977 administered alone, and following a single dose of edoxaban (PER977-P1). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01826266. Updated September 25, 2014. Accessed September 29, 2014
   Google Scholar
• . Ansell JE, Laulicht B, Bakhru S,. PER977 reverses unfractionated and low molecular weight heparins, fondaparinux and new Xa and II a anticoagulants: a report of phase I/II clinical trial with edoxaban. Oral presentation at the European Society of Cardiology congress; Barcelona, Spain: September 3, 2014
   Google Scholar
• . National Institutes of Health. Study of PER977 administered to subjects with steady state edoxaban dosing and re-anticoagulation with edoxaban. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02207257. Updated September 25, 2014. Accessed September 29, 2014
   Google Scholar
• . National Institutes of Health. Safety, tolerability, pharmacokinetics and pharmacodynamic effects of single, escalating doses of PER977 following a single dose of enoxaparin. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02206100. Updated August 1, 2014. Accessed September 29, 2014
   Google Scholar
• . National Institutes of Health. Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PER977 following heparin. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02206087. Updated September 25, 2014. Accessed September 29, 2014
   Google Scholar
• . Aminocaproic acid injection, solution prescribing information. DailyMed. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4f65667-c349–420b-b7b7-f20f3a4e4d4e. Updated February 2014. Accessed September 29, 2014
   Google Scholar
• . Bebulin (factor IX complex) prescribing information. Baxter. http://www.baxter.com/downloads/healthcare_professionals/products/bebulin_pi.pdf. Revised July 2012. Accessed September 29, 2014
   Google Scholar
• . Beriplex P/N 1000 (human prothrombin complex) prescribing information. CSL Behring. http://labeling.cslbehring.com/PI/CORE/Beriplex/EN/Beriplex-Prescribing-Information.pdf Revised January 2013. Accessed September 29, 2014
   Google Scholar
• . FEIBA NF, anti-inhibitor Coagulant Complex prescribing information. Baxter. http://www.feiba.com/us/forms/feiba_nf_pi.pdf. Revised February 2011. Accessed September 29, 2014
   Google Scholar
• . NovoSeven RT (coagulation factor VIIa) recombinant prescribing information. Novo Nordisk A/S. http://www.novo-pi.com/novosevenrt.pdf. Revised July 2014. Accessed September 29, 2014
   Google Scholar
• . PROFILNINE SD (factor IX complex) prescribing information. Grifols Biologicals Inc. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM261964.pdf. Revised August 2010. September 29, 2014
   Google Scholar
• . Tranexamic acid injection, solution prescribing information. DailyMed. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81916afc-f83a-4bba-a810–17393980e27e. Revised January 2014. Accessed September 29, 2014
   Google Scholar
• . Kcentra (prothrombin complex concentrate, human) for intravenous use, prescribing information. CSL Behring. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM350239.pdf. Accessed September 29, 2014
   Google Scholar